Mode
Text Size
Log in / Sign up
N/A N=38 Supportive Care

Training Induced Muscle Exosome Release

Metabolism

Enrolled (actual)
38
Serious AEs
0.0%
Results posted
Jan 2024
Primary outcome: Primary: miR-1 Abundance — 226; 110; 286 percent change

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Acute Resistance Exercise (Behavioral)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Yuan Wen
Primary completion
Nov 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
miR-1 Abundance
226; 110; 286

Summary

The primary objective of this study is to quantify miR-1 release from muscle in extra-cellular vesicles following an acute resistance exercise bout and potential delivery to subcutaneous adipose tissue in young healthy and obese adults.

Eligibility Criteria

Inclusion Criteria

  • 18-30 years of age.
  • Either BMI 30.
  • Relatively sedentary, reporting no participation in regular (>1 day per week) exercise for at least the past 3 months.
  • Non-smoker.

Exclusion Criteria

  • BMI between 25 and 30.
  • Evidence or signs and symptoms for cardiovascular disease (previous heart attack, arrhythmias, angina, shortness of breath, extreme fatigue, unusual pain in neck, jaw, throat, upper abdomen, or back, swelling in feet, legs, or ankles).
  • Evidence or signs and symptoms of metabolic syndrome or disorder (diagnosis of diabetes or insulin resistance, elevated BP, high fasting blood sugar, abnormal cholesterol or triglyceride levels).
  • Chronic aspirin or NSAID use (unless it can be safely stopped prior to the biopsies), and any other use of an anticoagulant (e.g., Coumadin) or history of bleeding including history of hypo- or hyper-coagulation disorders.
  • Neurological, musculoskeletal, or other disorder that would preclude safe participation in the weight lifting tasks and all performance tests.
  • Any other medical condition that would interfere with testing or increase one's risk of complications during exercise, as judged by the study physician.
  • Any other condition or events considered exclusionary by the PI and/or physician, such as non-compliance.
  • Lidocaine allergy (1% lidocaine is the local anesthetic used during the muscle biopsy procedure).
  • Pregnancy.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04500769). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search